Of the therapies reviewed here, the benefit from the use of TMZ, SRL, and DA in NFPA is most well-documented, while the potential benefit of ICIs, VEGF inhibitors, and PRRT is largely unknown. The gene discussed is VEGFA; the disease is non-functioning pituitary adenoma.